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Synopsis
Given the severity of their illness and lack of effective disease modifying agents, it is not 
surprising that most patients with ALS consider trying complementary and alternative therapies. 
Some of the most commonly considered alternative therapies include special diets, nutritional 
supplements, cannabis, acupuncture, chelation and energy healing. This chapter reviews these in 
detail. We also describe 3 models by which physicians may frame discussions about alternative 
therapies: paternalism, autonomy and shared decision making. Finally, we review a program 
called ALSUntangled which using shared shared decision making to review alternative therapies 
for ALS.
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I. Introduction
Complementary and alternative medicine (CAM) is defined as non-mainstream treatment 
used in addition to (complementary) or instead of (alternative) standard evidence-based care 
(1). At some point in their illness, the majority of people with ALS (PALS) will try at least 
one type of CAM (2,3). It is easy to see why. ALS rapidly disables and shortens the lifespan 
of its victims. While symptom management has improved in recent years (4–6) there 
remains no evidence-based clinically meaningful disease-modifying therapy for this dreaded 
condition. Surveys shed light on patient motivations and expectations for ALS CAMs: 10% 
believe they will find a cure, 30% believe they will improve, 50% believe they will slow 
progression (2,3). Other drivers we have encountered include peer pressure from family 
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members and friends who have these expectations, and the belief that nothing worse than the 
present disease could possibly be encountered.
The Internet has made it easier than ever for PALS to find CAMs. A Google search of “ALS 
Treatment” for example, yields more than 100 million hits (7). While this breadth is 
impressive, there is often little depth within websites offering CAMs. Claims such as 
“clinically proven”, and “perfectly safe” are too-often supported by data that ranges from 
absent, to flawed, to completely inaccurate. Real harms have come to PALS pursuing 
CAMs, including physical, financial, and psychological harms (8,9). There is also the 
potential for scientific harms, as pursuit of CAM is sometimes undertaken in place of 
enrollment in a trial, meaning trials may take longer, cost more and have to be stopped 
prematurely due to poor enrollment (10).
In this chapter we will describe the types of ALS CAMs that we have been asked about most 
often over the years. We will then discuss options for reviewing CAMs with PALS, 
including one called ALSUntangled.
II. Types of CAM that PALS Commonly Ask About
A. Diets and Nutritional Supplements
The importance of energy balance is well established in ALS, with both pre-clinical and 
human studies offering evidence to support a disease influencing effect of premorbid weight, 
weight maintenance and caloric intake (11–13). While studies in the healthy population 
suggest that reduced caloric intake provides survival benefits by reducing the risk for 
chronic disease, the opposite is true in ALS. ALS SOD1-mutant mice placed on a calorie-
restricted diet showed reduced paw-grip strength and significantly reduced survival 
compared to animals receiving adequate nutrition (14). In contrast, several studies 
examining the effects of high calorie diets enriched in carbohydrates or fat have shown 
prolonged survival in SOD1 animals (15–18).
Evidence supporting a survival benefit related to energy balance in ALS patients has been 
collected primarily from population studies that include assessment of BMI and 
malnutrition. Malnutrition in ALS has been defined as the loss of greater than 10% baseline 
body weight or a body mass index (BMI) lower than 18.5 kg/m2; both are considered 
negative predictors of survival in ALS. While the prevalence varies between studies, some 
report over half of all ALS patients meet criteria for malnutrition (19). The literature 
consistently shows that a higher BMI, between 30 to 35 kg/m2, is associated with decreased 
risk of disease, later disease onset and prolonged survival (20). Low BMI or rapid weight 
loss negatively effects disease progression with reports suggesting a 7.7 fold relative risk of 
mortality in malnourished ALS patients (21). In addition, Lindauer et al. in their prospective 
study, assessing adiposity by MRI imaging, reported that increased subcutaneous fat mass 
was a statistically significant predictor of survival in men (22).
Weight loss is nearly ubiquitous in ALS and presents significant challenges for patients. In a 
cohort of 121 patients, queried by Korner et al., weight loss had a negative impact on quality 
of life with perception of reduced physical functioning and vitality. Patients who had lost 
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weight and were subsequently placed on high calorie supplements or had undergone PEG (n 
= 23) reported weight stabilization or gain. Of those who chose PEG, 84.6% reported an 
improvement in QOL with no patients reporting worsened QOL (23). The etiology of weight 
loss and subsequent malnutrition in ALS is multifactorial and includes dysphagia from 
bulbar dysfunction, upper extremity weakness, and hypermetabolism. Dysphagia is present 
in 45% of patients with bulbar onset disease at diagnosis, and approximately 81% of all ALS 
patients will experience dysphagia as a symptom of ALS (23). Due to the involvement of 
cranial nerves IX, X and XII, patients with bulbar disease develop disruption in tongue, 
pharyngeal and esophageal function resulting in difficulty chewing and swallowing. The 
weakened oral activities ultimately result in reduced calorie and fluid intake as patients often 
become fearful of choking and avoid eating and drinking, or are unable to spend the 
increased time it takes to consume a meal safely. Upper extremity weakness also interferes 
with weight maintenance as it impairs self-feeding and prolongs mealtime, which often 
results in early satiety and reduced caloric intake. Dietary modification, with changes in 
food texture and liquid viscosity, as well as behavioral modification, including safe 
swallowing techniques and caregiver assisted feeding, may help mitigate these problems, at 
least temporarily.
Hypermetabolism, defined as an increased resting metabolic rate, has been observed in ALS 
patients and SOD1 mice. The etiology of the hypermetabolism in ALS is poorly described, 
but has been attributed to increased energy utilization by weakened skeletal muscles; 
nonfunctional muscular activity such as spasticity, cramps, fasciculations, and/or 
pseudobulbar motor activities (uncontrolled laughing or crying); and the metabolic cost of 
increased protein catabolism (24,25). Calculating the total daily energy expenditure for ALS 
patients using standard methods such as the Harris-Benedict Equation does not provide 
adequate estimation of total daily energy expenditure. It has been suggested that ALS 
patients require anywhere from 10–20% more calories than what these predication strategies 
indicate. Kasarskis et.al. followed 80 individuals with ALS and their data provided evidence 
supporting the presence of hypermetabolism early in disease and the potential for broad 
fluctuation of energy imbalance within a single ALS patient (−2989 to +1395 kcal/d), 
illustrating the complexity of metabolic changes in ALS. This presents a challenge to the 
practitioner for providing accurate estimates and recommendations to meet each patient’s 
nutritional needs over the course of disease. From their data, the authors (26) developed a 
more accurate caloric estimation tool using the ALSFRSr and the Harris-Benedict Equation; 
both patients and practitioners can access this tool online and use it to guide nutrition related 
interventions including the need for gastrostomy (27).
There have been conflicting opinions regarding the best diet to recommend for nutritional 
support in ALS. Some propose a diet high in carbohydrates while others recommend a diet 
high in fat. Still others hypothesize that a ketogenic diet may have therapeutic potential in 
ALS based on preclinical data in SOD1 mice showing strength gains mid-disease when 
compared to mice fed a traditional diet (28). While high calorie diets have shown survival 
benefit in SOD1 mice, the ketogenic diet did not. In a recent clinical trial, comparing the 
potential of high calorie diets enriched with either fat or carbohydrates to restore weight in 
24 individuals with ALS, both strategies were reported as safe and effective after 12 weeks 
of treatment (29). However, there was a trend toward greater weight gain that did not reach 
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statistical significance for those who consumed the high fat diet. This study was limited by 
small sample size and no conclusion could be drawn about survival, as this was not an end 
point. In contrast, a second small but randomized, double blind, placebo controlled phase II 
clinical study (n=24) compared the safety and tolerability of three diets; a regular diet (jevity 
1.00; 29% fat calories), a hypercarbohydrate hypercaloric diet (Jevity 1.5; 29% fat calories), 
and a hyperfat hypercaloric diet (Oxepa; 55% fat calories with eicosapentaenoic acid and 
gamma-linolenic acid) with differing results (30). While this study was also limited by 
sample size, the data favored those who were treated with the hypercarbohydrate 
hypercaloric diet, who had fewer serious adverse events including death during the 5 month 
follow-up period (control deaths 3 of 7; HF/HC deaths 1 of 8; HC/HC deaths 0 of 9). 
Interestingly, the hyperfat hypercaloric cohort lost weight during the trial calling into 
question the accuracy of their methods for assessing calorie requirements. In addition, 
preclinical data assessing the benefits of omega 3 fatty acids, and more specifically 
eicosapentaenoic acid, in ALS SOD1 mice showed reduced survival in the animals receiving 
the omega 3 fatty acid (31). The authors cautioned against its use in ALS. Further testing 
with a larger sample, and perhaps using a different hyperfat hypercaloric supplement is 
needed. However, there appears to be sufficient data to conclude that a diet high in calories 
provides benefit in ALS.
When ALS patients are unable to overcome negative energy balance and lose more than 10 
percent of baseline body weight a gastrostomy tube is often indicated. Argued advantages of 
gastrostomy include alleviation of patient and family stress, improvement in quality of life 
and increased survival. While this has remained somewhat controversial, there is a growing 
body of evidence to support these benefits. Numerous studies have measured mortality rate 
post procedure with respiratory insufficiency being the most common cause of peri-
procedural death. The AAN recommends that gastrostomy be placed when the force vital 
capacity is equal to or greater than 50% predicted to reduce associated risks (32). A study of 
35 ALS patients with FVC greater than 50%, observed in three month intervals post PEG 
tube placement for up to 2 years, did not differ significantly in mortality from patients 
without PEG at 6 months, but did after 6 months, having lower mortality and significant 
improvement in BMI (33). Intra-procedural mortality of percutaneous gastrostomy has been 
shown to be 1.8%, 24-hour in-hospital mortality rate 3.6%, and 30-day mortality rate 11.5% 
(34). More recently, Dorst et al. followed 89 patients in a multi-center prospective study 
observing the safety of percutaneous endoscopic gastrostomy (PEG). They reported general 
safety of PEG placement with only 1.1% mortality in the peri-procedure period. In addition 
they had improved outcomes in patients receiving, single prophylactic injection of 
antibiotics during tube placement, slow initiation of nutritional supplementation (<200 kcal/
day), and high calorie nutritional supplementation once at goal (35). There were no reports 
of refeeding syndrome and the patients who received high calorie supplementation showed a 
survival benefit at 18 months post gastrostomy placement. In addition, the authors 
concluded that the use of non-invasive ventilation in the peri-procedure period decreased the 
risk associated with PEG, allowing safe placement later in disease. However, some suggest 
that radiologically placed gastrostomy (RIG) is safer than PEG (36).
If nutrition has such a strong influence on disease onset and progression, are there disease-
modifying effects of vitamin and mineral enriched diets? Supplements or “nutraceuticals” 
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are ” products intended to supplement the diet that contain one or more of the following 
dietary ingredients: a vitamin; a mineral; an herb or other botanical; or an amino acid used 
as a dietary substance for man to supplement the diet by increasing the total dietary intake to 
promote wellness (37).” Since the passing of the Dietary Supplement Health and Education 
Act of 1994 supplements have not been regulated by the FDA and are widely available and 
easily obtained without physician oversight. In fact, there are few requirements, other than 
registering the manufacturing plant and following rules for labeling, that manufacturers have 
to meet to produce supplements or ensure product quality and safety. It is estimated that 
over 50% of United States citizens take supplements regularly for health. The prevalence of 
supplement users is even greater in the ALS community, with more than 75% of patients 
taking supplements as part of their health regimen (32,38). In the setting of a terminal 
disease without ample choices for disease-modifying therapies, these patients assert their 
autonomy and report that they self-medicate with dietary supplements to improve general 
wellbeing and slow disease progression (3). Importantly, as described in a study of 121 ALS 
patients, those who took supplements (52%) reported greater vitality, physical and social 
functioning, and an overall improved quality of life (QoL) in the early and mid-stages of 
disease (23). Whether this benefit was afforded or not by the physiologic effects of the 
supplements can be debated; however the health benefit, as measured by QoL, of a self-
determined choice should not be considered trivial and may be tightly bound to a patient’s 
hope for improved health and prolonged life. While the vast majority of supplements have 
little or no supporting scientific evidence to back their use, patients will take them. 
Rosenthal and Ellis in their review of nutrition and dietary supplements for motor neuron 
disease, suggest that it is the responsibility of the practitioner to remain aware of known 
adverse effects and “offer advice or caution as our patients explore their own therapeutic 
combinations (39).”
The Deanna Protocol is a supplement regimen that many PALS currently ask about. It was 
developed by an orthopedic physician who became frustrated by the lack of effective 
disease-modifying treatments when his daughter was first diagnosed with ALS (40). The 
regimen combines multiple supplements targeted to improve mitochondrial function and 
cellular energy production, and to provide neuroprotection. The exact regimen itself 
changes; the most recent version can be found on the “Winning the Fight” website (41). This 
website reports “Scientific studies have proven that the Deanna Protocol significantly slows 
the progression of ALS and extends life span (41).” We are aware of only 1 published study 
on the Deanna Protocol, and this was done in animals. Poff and colleagues compared 
standard and ketogenic diets, both with and without added key supplements from the 
Deanna Protocol in SOD1 mutant mice (42). Their data demonstrated significant 
improvements in function mid-disease, and prolonged longevity in animals fed both the 
supplemented diets compared to the non-supplemented diets. Furthermore, the supplement 
enriched standard diet provided the longest and most statistically significant survival benefit 
(7.5% increase; p=0.001), while the mice fed the supplement enriched ketogenic diet 
showed the earliest functional benefit with a shorter but still significant increase in survival 
(4.2% increase; p=0.006). This animal study has multiple methodological flaws identified by 
published guidelines (43) and has not been independently replicated. There are anecdotal 
reports of patients having improved energy and slowed progression on the Deanna Protocol, 
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but neither the ALS diagnosis nor the reported improvements could be independently 
validated (40). The cost to obtain the entire supplement list from one version of the protocol 
has been estimated to be greater than $400.00 per month and is not reimbursable by 
insurance (40). Further investigations are warranted to evaluate its efficacy.
Although limited, both pre-clinical and clinical studies have been completed for various 
nutritional supplements in ALS. Below is a select list of supplements, most with antioxidant 
properties, that have been proposed as potentially beneficial for the ALS Patient.
Catechins—Catechins are polyphenolic flavonoids which possess strong antioxident 
properties and include, epigallocatechin, epicatechin, and epicatichin-3-gallate. Catechins 
are considered free radical scavengers found in high concentrations in some plants, fruits 
and vegetables. They are considered the health promoting constituent of green tea, blue 
berries, cocoa, prune juice, red wine, and Ginko Baloba to name a few. Studies have shown 
that catechins cross the blood brain barrier and are incorporated into brain tissue where they 
exert potent neuroprotective actions by modulating mitochondrial responses to oxidative 
insults. Clinical studies in Parkinson’s disease have had promising results, however, no 
clinical studies have been completed in ALS. Supporting biologic plausibility for catechins 
in the treatment of ALS, in vitro studies revealed that epicatichin-3-gallate reduced 
hyperexcitability in SOD1 motor neurons by interfering with glutamate hyperexcitability, 
and had a rescue effect in motor neurons exposed to H2O2 (44). Preclinical investigation in 
the G93A SOD1 mouse showed that pre-symptomatic oral administration of epicatichin-3-
gallate significantly delayed the onset of disease, and extended life span. In addition, the 
treated mice had increased number of motor neurons, diminished microglial activation, 
reduced immunohistochemical reaction of NF-kappaB and cleaved caspase-3 as well as 
reduced protein levels of iNOS and NF-kappaB in the spinal cords.
Co-Q10—Co-enzyme Q10 (CoQ10) is a fat soluble vitamin-like substance found in 
mitochondria, that is part of the electron transport chain, participating in aerobic cellular 
respiration and the generation of ATP. Both pre-clinical and clinic studies have been 
completed assessing CoQ10 in ALS. SOD1 transgenic mice, fed daily CoQ10, demonstrated 
an increase in survival by 6 days compared to controls, which met modest statistical 
significance (45). Although high doses of up to 3000mg/day were well tolerated in patients 
(46), a phase II clinical trial did not confirm superiority of CoQ10 when compared to 
patients taking placebo (47). Advancement to a phase III clinical trial was not 
recommended.
Creatine—Creatine is a nitrogenous organic acid that participates in cellular energy 
production. In addition, creatine appears to have neuroprotective properties related to its role 
in stabilizing the mitochondrial membrane by suppressing the opening of the mitochondrial 
permeability transition pore and release of cellular pro apoptotic factors (48). In ALS, 
supplementation with creatine was found to improve motor performance, improve weight 
maintenance and extend survival in G93A transgenic mice (49). However, a second group 
showed no effect of creatine on muscle bulk and strength in SOD1 mice (50). A randomized 
double-blind, placebo controlled trial in humans, did not show significant benefits (51,52). 
A recent Cochrane review, including 3 trials and 386 ALS participants taking creatine, by 
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Bedlack et al, concluded that “in patients already diagnosed with clinically probable or 
definite ALS, creatine at doses ranging from 5 to 10 g per day did not have a statistically 
significant effect on survival, ALSFRS-R progression or percent predicted FVC progression 
(53).” However, it is unknown if, at higher doses, creatine may be beneficial to PALS (54). 
Interestingly, a recent phase II study showed that high dose creatine supplementation is safe, 
tolerable, and may have some positive effects in Huntington Disease. We await further 
studies with high dose creatine in ALS patients to determine whether it is beneficial.
Ibedenone—Idebenone is quinone anologue of CoQ10 that was developed in Japan in the 
1980’s for the treatment of neurodegenerative disorders. Idebenone is an antioxidant that has 
been shown to inhibit lipid peroxidation in brain mitochondria. In one series, Idebenone was 
the most potent antioxidant of 70 related quinones evaluated (55). Idebenone has been most 
extensively evaluated in patients with Friedreich’s ataxia, a trinucleotide repeat disorder 
with impaired iron metabolism and redox homeostasis (56). The result of multiple clinical 
trials in this patient population have been mixed ranging from documented improvement in 
function to lack of efficacy (56,57). While there are concerns that Idebenone has the 
potential to form superoxide radicals causing increased cellular damage, it was well 
tolerated in all clinical studies and was subsequently marketed in Canada. However, in 2013, 
Santhera Pharmaceuticals voluntarily pulled it from market, citing lack of efficacy (57). 
Idebenone continues to be available online through neutraceutical providers, and is included 
as one of the key supplements in the Deanna Protocol. While clinical trials are ongoing in 
multiple sclerosis and other neuromuscular diseases, no preclinical or clinical studies have 
been published in ALS.
L-Carnitine—An essential cofactor for the beta-oxidation of long-chain fatty acids, L-
carnitine is a quaternary ammonium compound required for the transport of fatty acids into 
the mitochondrial matrix for use in energy metabolism. Its antioxidant properties include 
superoxide anion radical and hydrogen scavenging that reduces mitochondrial injury and 
apoptosis both in vitro and in vivo (58). In transgenic mice carrying a human SOD1 gene, 
oral L-carnitine significantly delayed the onset of signs of disease, delayed deterioration of 
motor activity, and extended life span (59). Furthermore, subcutaneous injection prolonged 
survival even when treatment was initiated after the onset of symptoms (59). A small (n=42 
treated, 40 placebo) randomized double-blind placebo-controlled pilot study of acetyl-L-
carnitine, showed an increase in median survival and slower ALSFRS-R and FVC decline in 
the patients taking L-carnitine 3g/day. No significant side effects were reported and the 
authors concluded that a phase III trial is needed to confirm these preliminary findings (60).
Omega-3—Omega-3 polyunsaturated fatty acids have been associated with significant 
health benefits (61). Omega 3 is thought to reduce neuroexcitotoxicity and 
neuroinflammation, and activate anti-apoptotic pathways (62). In a study combing the data 
from 5 large prospective cohorts, there was an associated reduced risk for developing ALS 
in those consuming a diet high in omega 3 polyunsaturated fatty acids (63). A single 
preclinical study has been completed in transgenic SOD1 mice to evaluate disease-
modifying effects of omega 3 (64). They fed the mice a diet high in eicosapentaenoic acid, a 
murine derived omega 3 fatty acid. Omega 3 did not affect the course of motor deficit or the 
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length of survival, whether administered at disease onset or if given during the symptomatic 
stage of the disease, and accelerated disease progression in those fed omega-3 during the 
pre-symptomatic stage of ALS. Those animals fed omega 3 fatty acids showed an increase 
in vacuolization of anterior horn cells and associated glial cells abnormalities. In their 
conclusion, the authors advised against the use of omega-3 supplementation in patients with 
ALS (64). While there have been no clinical trials directly assessing the efficacy of a diet 
high in omega 3 fatty acids, a small clinical trial discussed earlier in this chapter, did 
compare a standard diet, high carbohydrate diet and a high fat diet with 55% of its calories 
provided by omega 3 fatty acids. The high fat diet had increased adverse events including 
deaths, as compared to the high carbohydrate diet (29,30).
Resveratrol—Resveratrol is a polyphenol found in the skin of grapes, blueberries, 
raspberries and mulberries. It is reported to have neuroprotective effects through cellular 
pathways affecting mitochondrial biogenesis and autophagy, with implicated pathways 
activating Surtuins, AMPK and PGC-1alpha. A few pre-clinical studies have been 
completed studying the effects of Resveratrol (65–67). All studies reported a delay in 
disease onset and statistically significant increases in survival. In addition, Resveratrol 
improved survival with post disease onset treatment in the SOD1 ALS mouse model (65–
67). Over 30 clinical trials have been conducted examining the effects of Resveratrol in 
cancer, diabetes and heart disease, to name a few (68). The supplement has had varying 
affects but has been well tolerated in all the studies. There have been no clinical trials in 
patients with ALS.
Vitamin A—Vitamin A is a fat soluble vitamin with multiple functions including growth 
and development, vision, and maintenance of the immune system. While some authors have 
suggested that retinoid signaling is altered in ALS, serum vitamin A levels have been 
evaluated and have not differed from controls (69). A pre-clinical investigation using 
transgenic ALS mice, demonstrated shortened lifespan in mice receiving daily retinoic acid 
supplementation. The authors cautioned against its use in ALS (70). There have been no 
human clinical trials assessing the efficacy of retinoic acid.
Homocysteine—Homocysteine is involved in the formation of free radicals and cytosolic 
calcium accumulation, mitochondrial dysfunction, apoptotic pathway activation, and 
excitotoxic amino acid–mediated damage (71). These pathological pathways have been 
implicated in ALS. A small clinical study found that plasma homocysteine levels are 
increased in PALS compared with healthy controls. PALS with shorter time to diagnosis 
were found to have higher homocysteine levels. The authors concluded that a higher plasma 
homocysteine may be linked to faster progression of the disease (72). Another small study 
showed that homocysteine level in the cerebrospinal fluid is also increased in patients with 
ALS compared to healthy controls. The authors hypothesized that homocysteine may be a 
biomarker of ALS and may be involved in the pathophysiology (73). Folate and vitamin B12 
are thought to reduce the level of homocysteine via remethylation. Studies using SOD1 
mouse models have shown a beneficial effect of folate on reducing the levels of 
homocysteine, delaying onset of disease and prolonging lifespan (74). However, in one 
study, B12 alone did not show any effect on homocysteine levels, onset of disease or 
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survival. However, a more recent in vitro study had opposite results, showing better survival 
against homocysteine toxicity in vitro, in cells pretreated with B12 but not in those treated 
with folate (75). Furthermore, in one small pre-clinical study, ALS mice were supplemented 
with Galactooligosaccharides (GOS), a prebiotic that is thought to improve the absorption 
and synthesis of B Vitamins. GOS and prebiotics yogurt administration were shown to 
significantly delay the disease onset and prolong the lifespan in SOD1G93A mice. Also, 
these products increased the concentration of folate and VitB12, and reduced the level of 
homocysteine (76). However, there have been no clinical trials examining the role of B12, 
folate or GOS supplementation in ALS.
Thiamine—Thiamin-thiamin monophosphate (T/T TMP) ratio has been shown to be 
reduced in the CSF of PALS in 2 small studies. There have been no studies evaluating 
supplementation with thiamin (vitamin B1) in PALS (77,78).
Riboflavin—Riboflavin or vitamin B2 supplementation was evaluated in one pre-clinical 
study using the SOD1 transgenic mouse model. There was no significant effect of riboflavin 
on either survival or motor performance (79).
Vitamin C—Vitamin C is considered an antioxidant but several studies have failed to show 
an association between vitamin C intake and ALS progression (80). There have been no 
ALS clinical trials addressing vitamin C supplementation.
Vitamin D—Vitamin D is a fat-soluble secosteroid. Sources of vitamin D include direct 
skin exposure to sunlight, few foods, and dietary supplements. Skin exposure to ultraviolet 
B radiation from the sun provides the predominant source of vitamin D. After hydroxylation 
in the liver and kidney to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D respectively, 
the active metabolite binds to the vitamin D-receptor in a cell, and induces transcription of a 
responsive gene. The vitamin D receptor has been found in many tissues including motor 
neurons, bone and muscle cells suggesting wide physiologic influence. Vitamin D 
participates in several distinct pathways that are potentially important in ALS 
physiopathology including calcium regulation and potentiation of protective neurotrophic 
factors (81). In a retrospective study of 74 ALS patients, risk of death was significantly 
increased in those with severe vitamin D deficiency (<25 nmol/L) compared to patients with 
normal vitamin D (82). The authors concluded that serum vitamin D may be a reliable 
prognostic indicator (82). Supplementation with vitamin D in ALS mouse models has 
yielded mixed results (83–85). A small clinical study showed that patients with ALS tended 
to have low vitamin D levels and that oral vitamin D supplementation with 2000 I.U./day 
was safe and may be of benefit (86). Screening for 25-OH vitamin D deficiency and 
providing vitamin D3 supplementation for those who are deficient is reasonable (87).
Vitamin E—Vitamin E is a fat soluble antioxidant comprised of tocopherols and 
tocotrienols. Studies in transgenic mice have shown that vitamin E can delay the onset of 
ALS but does not affect survival (88). Randomized trials of vitamin E supplementation did 
not prove efficacy (89,90). Interestingly, vitamin E intake may reduce the risk of developing 
ALS (91). Patients who chose to augment their vitamin E by supplementation should be 
cautioned that hypervitaminosis E can increase the risk of bleeding.
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There is a growing body of evidence that that cannabinoids (the active ingredient in 
cannabis) may hold a significant therapeutic benefit for patients with amyotrophic lateral 
sclerosis (ALS). Moreover, through manipulation of the endocannabinoid system, cannabis 
may hold disease-modifying potential in ALS (92–105). There are a number of animal 
studies suggest that the endocannabinoid system is implicated in the pathophysiology of 
ALS (93–99). This may be through a direct action or disease mechanism. Conversely this 
may be as part of a failure of homeostatic functioning of the neuromuscular system that may 
be governed by this system. There is now good animal based evidence that that cannabinoids 
are capable of slowing disease progression of ALS in mice (93–96). The mechanisms are not 
entirely clear but it is likely this occurs partially by cannabinoids acting as anti-oxidants and 
neuromodulators, although other mechanisms are likely as well.
Cannabis has also been reported to be useful in managing the symptomatology in ALS 
(104). There are many symptoms of the disease, including pain, spasticity, loss of appetite, 
depression, and management of saliva that could be helped by cannabis use. In a survey of 
131 patients with ALS, those who were able to obtain cannabis found it preferable to 
prescription medication in managing their symptoms (104). However, this study also noted 
that the biggest reason ALS patients were not using cannabis was their inability to obtain it, 
either due to legal or financial reasons or lack of safe access (104).
Thus there could be a potential dual role of cannabis for both clinical symptom management 
and a positive disease-modifying effect. There are both physiological and pharmacological 
mechanisms identified to support these roles. The basic mechanism of action for cannabis is 
the endocannabinoid system. Our understanding of the receptors and ligands composing the 
endogenous cannabinoid system has increased tremendously over the past few decades 
(106–111). There are now identified 2 major cannabinoid receptor subtypes (111,112). The 
type 1 (CB1) cannabinoid receptor is predominantly expressed in the central nervous system 
(CNS), while the type 2 (CB2) receptor is primarily found in the peripheral nervous system 
(PNS), immune system, cardiovascular and gastrointestinal systems, among others.
Biochemistry of the Cannabis Plant—The cannabis plant is complex, with several 
types of subtypes of cannabis, each containing over 400 chemical moieties (113,114). 
Approximately 60 are chemically classified as cannabinoids (114). The cannabinoids are 21 
carbon terpenes, biosynthesized predominantly via a recently discovered deoxyxylulose 
phosphate pathway (115). The molecular mechanism of action of the cannabinoids became 
much more clear with the characterization and cloning of the CB1 and CB2 receptors. 
Interestingly while these receptors appear to mediate most of the pharmacological actions of 
cannabis, there may be other orphan receptors for plant based cannabinoids 
(phytocannabinoids)(115,17). There are other natural plant based compounds, including 
flavonoids, which are structurally similar to phytocannabinoids. Over the last decade, a 
number of potential alternative receptors for phytocannabinoids have been suggested, based 
on ligand binding studies. This may also extend to the endocannabinoids, and possibly even 
synthetic cannabinergic drugs (116). The most recent data on these emerging “non-CB1, 
non-CB2 receptors cannabinoid receptors” suggests that there are still many uncharacterized 
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or “orphan” endocannabinoid mediated G-protein-coupled receptors that have yet to be fully 
delineated. Moreover there are likely a whole host of cannabis plant based terpenoids that 
may hold therapeutic promise, including compounds such as limonene and myrcene. (118). 
Terpenoids share a precursor with phytocannabinoids, but display unique therapeutic effects 
that may contribute meaningfully to the entourage effects of cannabis-based medicinal 
extracts. There continues to be growing evidence that these non-cannabinoid components 
from the cannabis plant may have tremendous therapeutic potential for disease such as ALS, 
without any intoxicating effects (118).
The cannabinoids themselves are all lipophilic and not soluble in water. Among the most 
psychoactive of the cannabinoids is delta-9-tetrahydrocannabinol (THC), the active 
ingredient in dronabinol (119). This is the primary intoxicant in cannabis. Other major 
cannabinoids include cannabidiol (CBD) and cannabinol (CBN), both of which may modify 
the pharmacology of THC or have distinct effects of their own (120). CBD is not 
psychoactive but has significant anticonvulsant, sedative, and other pharmacological activity 
likely to interact with THC (121–125).
Clinical Uses Cannabis in Patients with ALS—The cannabinoids found in cannabis 
have many pharmacological mechanisms of action that can be immediately useful to help 
manage clinical symptoms in ALS. For example, cannabinoids been shown to produce an 
anti- inflammatory effect by inhibiting the production and action of tumor necrosis factor 
(TNF) and other acute phase cytokines (102). Additionally, cannabis may reduce pain 
sensation, through action at peripheral, spinal, and supra-spinal levels. It likely also operates 
through a brainstem circuit that also contributes to the pain suppressing effects of morphine 
(126–128) Cannabinoids produce analgesia by modulating rostral ventromedial medulla 
neuronal activity in a manner similar to, but pharmacologically distinct from, that of 
morphine (127,128). Cannabinoids are centrally and peripherally acting analgesics with a 
different mechanism of action than opioids, although the analgesia produced by 
cannabinoids and opioids may involve similar pathways at the brainstem level. There are 
now multiple, well-controlled clinical studies using cannabis to treat pain, showing ample 
evidence of analgesic efficacy (129,130). A recent systematic review and meta-analysis of 
double-blind randomized controlled trials that compared any cannabis preparation to 
placebo among subjects with chronic pain showed a total of eighteen completed trials. The 
studies indicate that that cannabis is moderately efficacious for treatment of chronic pain 
(129,130). In the setting of ALS, cannabis use should be dose-titrated to the point of 
comfort. If additional opiate medications are needed to get effective pain control then the 
anti-emetic effect of cannabis may help with the nausea sometimes associated with use of 
opioids. Use of cannabis may lower the need for opiate medications and may be safely used 
concomitantly as the opioid receptor system is distinct from the cannabinoid system. 
Additionally, the use of cannabis does not cause respiratory suppression or decreased gut 
motility, which are particularly helpful in this setting.
In addition to pain, spasticity is also a major problem for patients with ALS. Cannabis has 
an inhibitory effect via augmentation of gamma-amino-butyric acid (GABA) pathways in 
the central nervous system (131–133). This produces motor neuron inhibition at spinal levels 
in mice. Several past studies have suggested that cannabinoid therapy provide at least a 
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subjective reduction of spasticity, although virtually all of the studies have been done in 
patients with multiple sclerosis (MS) (134–137). In addition to pain and spasticity, there are 
other pharmacological effects of cannabis that may be useful for ALS patients. Patients with 
ALS and bulbar symptoms also usually have difficulty controlling and swallowing the saliva 
that is normally present in the oral cavity. Cannabis is a potent anti-salivary compound that 
swiftly dries the oral cavity and upper airway, potentially reducing the risk for aspiration 
pneumonia and increasing patient comfort. Cannabis also increases appetite and may help 
prevent “ALS cachexia”, a phenomenon experienced by some patients where weight loss 
occurs in excess of that caused by muscle atrophy and reduced caloric intake. In addition to 
improving appetite, cannabis may also help with mood state and sleep. Patients with ALS 
previously have reported that cannabis is at least moderately effective at reducing symptoms 
of pain, spasticity, drooling, appetite loss, and depression (104).
The American Academy of Neurology recently published some excellent systematic 
literature reviews regarding the use of cannabis in neurological disorders as well as 
specifically in another neurodegenerative disorder, multiple sclerosis (MS) (136–137). The 
authors concluded that in patients with MS, oral cannabis extracts are effective to treat 
spasticity “painful spasms” as well as central pain. This included including spasticity-related 
pain. Risk of serious adverse psychopathologic effects was estimated to be approximately 
1%.
Route of administration is an important determinant of the pharmacokinetics of the various 
cannabinoids in cannabis, particularly absorption and metabolism (138). Cannabis does not 
need to be smoked to get a medical beneficial effect. Inhalation does have the advantage of 
rapid onset of effect and easy dose titration. However, due to their volatility, cannabinoids 
will vaporize at a much lower temperature than combustion, allowing them to be inhaled as 
a warm air mist, which is a much healthier option than smoking. Cannabinoids in the form 
of an aerosol in inhaled smoke or vapors are absorbed and delivered to the brain and 
circulation rapidly, as expected of a highly lipid-soluble drug. Cannabis may also be 
ingested orally, but this delivery route has markedly different pharmacokinetics compared 
with inhalation. The onset of action is delayed and titration of dosing is more difficult. 
Maximum cannabinoid blood levels are only reached up to 6 hours post ingestion, with a 
much longer half-life, as long as 20–30 hours (138). This would also apply to any orally 
ingested cannabinoid, including dronabinol (Marinol). Dronabinol is available as a Schedule 
III (CIII) controlled substance per the Drug Enforcement Agency (DEA) guidelines (138). 
The DEA still considers botanical cannabis as a Schedule I (CI) controlled substance, 
dangerous and without medical use (139). However, consider that natural cannabis contain, 
at best, 20% THC. As noted previously, there are beneficial physiological effects when the 
other cannabinoid forms are present, as is the case with natural cannabis plant material. 
Most patients with ALS would find likely find dronabinol too sedating and associated with 
too many psychoactive effects and it is not an appropriate substitute for natural cannabis. 
Finally the cannabinoids may also be made in to a liniment and absorbed through the skin, 
although this is the least efficient mode of delivery.
Although the medicinal use of cannabis is now allowed in a growing number of states in 
America, obtaining the medicine must be done through “cooperatives” as it will not be 
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available in a typical pharmacy. This may create varying degrees of psychological stress for 
patients with ALS and their caregivers (140). Moreover, third party payers and insurance 
companies will not likely pay for cannabis use even for medical use as it is not Food and 
Drug Administration (FDA) approved for any indication. As long as cannabis remaining as 
schedule one compound, there will not likely be much interest from the pharmaceutical 
industry to finance the massive costs of clinical trials needed to get FDA approval for a 
given indication.
C. Acupuncture
Acupuncture is a technique that involves the insertion of thin needles through the skin at 
specific points with the goal of achieving a therapeutic effect, most often pain reduction 
(141). Acupuncture originated in ancient China and is a key component of traditional 
Chinese medicine. In the West, several different acupuncture schools and modalities are 
available. There are traditional Chinese and Japanese techniques and “fusion” Contemporary 
Western approaches, and needle insertion is sometimes accompanied by the application of 
small electric currents (electroacupuncture) or injection of chemicals (acupuncture injection 
therapy) (141,142). Such diversity is a challenge when discussing the intended effects and 
results of acupuncture. It is also one of the reasons why few systematic studies exist on the 
topic as acupuncture treatments are highly individualized, dynamic, difficult to blind, and 
heavily dependent on practitioner training and experience. Acupuncture has been proposed 
as both a symptomatic ALS treatment (pain control) and a way to slow, stop or reverse 
progression (143–145).
Mechanism(s)—There are both traditional and modern theories on the mechanisms of 
acupuncture. Traditional Chinese Medicine (TCM) holds that an energy called “qi, ” which 
flows along specific paths or meridians, regulates body functions (141,142). Disease occurs 
when there are disruptions or blockages in the flow of this energy, and insertion of needles 
into specific locations (acupoints) restores energy flow and ameliorates disease (141,142). 
Science has yet to find convincing evidence for qi, meridians or acupoints (142,146,147).
More theories start with needle insertions activating vaso-active substances and 
neuropeptides such as histamine, calcitonin gene-related peptide (CGRP), neuropeptide Y, 
enkephalin, beta-endorphin, and dynorphin (142, 148–151). In fact, the skin around the 
needles often becomes red and a small weal can be seen under the skin. Needle manipulation 
by hand or addition of heat or electrical stimulation (electro-acupuncture) may potentiate 
these effects. Some of these substances, in turn are purported to have downstream effects on 
brain areas involved in pain perception (150). These substances may also modulate the 
immune system (151–154); in doing so, they could theoretically alter the progression of 
diseases where the immune system plays a pathogenic role, including ALS (155–156). 
Indeed, elevated beta-endorphin levels (150), altered functional MRI patterns, (156–161), 
and even altered inflammatory markers (162–165) including in ALS animal models 
(164,165) can occur following acupuncture. Opioid antagonists such as naloxone or genetic 
down regulation of opioid receptors can block the beneficial effects of acupuncture (150).
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However, even these modern theories have problems. They do not explain acupoints. 
“Sham” acupuncture utilizing telescoping needles that do not break the skin can sometimes 
work as well as “real” acupuncture, raising the possibility that acupuncture works via a 
placebo effect (142). The above described mechanistic studies do not yield consistent results 
across investigators (142).
Potential Uses in ALS—While the underlying mechanisms of acupuncture have not been 
completely elucidated, and may involve a significant placebo component, there is some 
evidence that it could help relieve 2 common ALS symptoms: pain (167–170) and spasticity 
(171).
More controversial is the possibility that acupuncture could slow, stop or reverse ALS 
progression. A small, flawed study in a mouse model of ALS showed that acupuncture was 
associated with improved motor neuron survival and delayed loss of motor performance 
compared to mice that did not receive any acupuncture (172). This has yet to be 
independently replicated. There is only 1 published trial of acupuncture in patients with ALS 
(173). In this trial, 18 patients were treated twice daily for 5 days, with before and after 
measurements of oxygen saturation, end-tidal carbon dioxide, respiratory rate, pulse rate and 
ALSFRS-R. Acupuncture treatments was associated with statistically significant 
improvements in oxygen saturation and pulse rate. However, the size of these improvements 
(mean oxygen saturation increased from 95.42% to 95.58% and mean pulse rate increased 
from 82.49 to 80.08) are of dubious clinical significance.
More impressive than the animal study or the small trial are 2 published case series 
describing the effects of acupuncture on ALS (174–177). Both these series describe 
improvements in motor function occurring with acupuncture. Unfortunately these reports 
suffer from the use of other treatments (such as Chinese herbs or detoxification regimens) at 
the same time as the acupuncture, lack of detail regarding the ALS diagnoses, lack of a 
control group, lack of blinding and failure to use validated ALS outcome measures (178).
Costs and Risks—Costs of acupuncture will vary greatly depending on the specific type 
and frequency. Within the online community PatientsLikeMe, members with ALS report a 
range of costs from less than $25 to more than $200 per month (179).
Large series suggest that acupuncture is generally safe but not entirely without risk. Serious 
adverse events have been described including cardiac tamponade (142,180), pneumothorax 
(142,181), and transmission of infections (142,182). Mild adverse events such as pain or 
bleeding occur in 7–11% of patients (142, 183–185).
D. Chelation
Chelation therapy is a medical procedure in which a chelating agent is administered to the 
patient with the objective of removing a specific heavy metal from the body. The chelating 
agent binds to the heavy metal inactivating its toxic effect. This soluble compound is then 
excreted from the body. The chelating agent can be administered intravenously, orally or 
intramuscularly.
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Approved Use—Chelation therapy is the main treatment for heavy metal poisoning. The 
chelating agent used depends on the type of metal to which the patient has been exposed. 
For example, Dimercaptosuccinic acid (DMSA) and Ethylenediamine tetraacetic acid 
(EDTA) are used in lead poisoning, and Dimercapto-propane sulfonate (DMPS) in arsenic 
and mercury poisoning.
Alternative Use—Chelation therapy has been, and continues to be used as an alternative 
therapeutic approach in various conditions including autism, cardiovascular disease and 
cancer. This practice is not based on scientific studies and may lead to death (186,187).
Use in ALS Patients—In spite of intense study over many years, there is no consistent 
evidence that any heavy metal toxicity can cause ALS (188,189). It should not be surprising, 
then, that there is no evidence that chelation therapy is useful for the treatment of ALS. In 
fact, there is evidence to the contrary. One case report (190) described an ALS patient with 
elevated blood level and massive urinary excretion of mercury which did not respond to 
chelation treatment with DMSA. Another case report described a patient who developed 
bulbar onset ALS in the setting of chronic lead intoxication from drinking water. Again, 
treatment with DSMA was administered for six months and had no effect on clinical course 
(191). Finally, a study where 53 patients with ALS or SMA and a control group were given 
DMSA did not show a difference in the urinary excretion of lead and mercury between the 2 
groups (192). A search of the World Wide Web reveals many other individual reports of 
patients who did not benefit from chelation therapy.
Risks—Chelation is generally felt to be a safe treatment when used properly. The use of 
sodium EDTA instead of calcium EDTA has resulted in severe hypocalcemia that lead to 
death in at least 3 reported patients (193). Another reported side effect is elevated creatinine 
reflecting potential kidney damage (187).
E. Energy Healing
Energy healing, which also includes spiritual and faith healing, is a branch of alternative 
medicine where the healer channels healing energy onto a patient in order to cure them from 
a certain disease. This is usually performed when the healer lays their hands on the patient, 
although some healers do an “off hands” method or even do remote healing with the patient 
being in a different location. There are many different types of energy healing. The most 
commonly used are spiritual healing and psychic healing, distant healing, intercessory 
prayer, therapeutic touch, healing touch, esoteric healing, Reiki, magnetic healing, Qigong 
healing, Pranic healing and Crystal healing. Some forms of energy healing use an 
“observable energy” such a magnet or light although in most cases, the energy is channeled 
via touch.
Energy Healing in Medicine—Energy healing has been studied in randomized, placebo-
controlled trials in multiple diseases such as asthma (194), cardiac bypass surgery (195), 
wound healing (196), postoperative oral pain (197), fatigue in breast cancer patients 
undergoing radiation therapy (198) and procedural pain in very preterm neonates (199). 
These robust studies have all shown no effect on the disease progression or symptoms.
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Energy Healing in ALS—There are no trials on the effect of energy healing in ALS 
patients. However, there are individual testimonials of improvement in patients with ALS 
with energy healing. One of these testimonials can be found on the webpage of Dean Kraft, 
one of the more famous energy healers in the United States. The following link: 
www.deankrafthealer.com/CaseHistory-NeldaBuss.html depicts the story of Nelda Buss, a 
patient diagnosed with ALS in 1985. Dean Kraft focused “a white stream of energy into her 
deteriorating respiratory system, her nerves…”. She subsequently regained significant 
muscle strength including regaining the ability to walk. The diagnosis and improvement in 
this patient were independently validated (200). Many other healers have their own webpage 
with a story on curing ALS. In addition, there is a documentary film on healing ALS 
pending funding http://healingals.com/. The movie’s mission is to educate people diagnosed 
with ALS and their families about holistic protocols for ALS that can slow, stop and even 
reverse the progression of ALS by showing multiple interviews with people who were 
diagnosed with ALS and had their disease cured through different holistic protocols. 
Unfortunately, along these claims of cure from ALS, there are many reports on ALS forums 
of lack of benefit, and high expenditure, with different type of energy healing. The fact that 
ALS can sometimes reverse spontaneously has to be considered as an alternate explanation 
for the above described improvements (201–203).
Costs and Risks—The costs of energy healing vary depending on the practitioner, 
methods and frequency. Dean Kraft charged Nelda Buss $75 per session and $25,000 overall 
(200).
There appear to be no serious risks for energy healing on patient’s health. However, some 
authors argue that promoting energy healing could be detrimental to patients and health care 
systems (204–206). According to the Ernst, for example, healing can be expensive and 
might divert patients from effective treatments. He argues that spiritual healing might 
promote the belief in a supernatural healing “energy,” which undermines rationality in 
general and hence boost pseudoscience (204–206). It could also potentially divert patients 
from adequate, scientifically studied treatments.
III. Options for Reviewing CAM with PALS
There are at least 3 models by which decisions get made in the doctor-patient relationship. 
These are all options for reviewing CAM with PALS in clinic. Here we review these models 
and options.
A. Paternalism
The oldest model, which has existed since the beginning of medicine, is paternalism. In this, 
the doctor acts as a parent or guardian and defines the patient’s goals and the methods for 
attaining these (207). Here, a patient’s question about an alternative therapy might be met 
with a phrase from the doctor like “That is not likely to help you and may even be harmful. I 
do not want you to pursue that.” There are several problems with this approach. While 
doctors do have many years of training and experience in evaluating care options, they may 
not always share the same goals, values and acceptable risk/benefit ratio with patients. This 
model ignores the fact that patients are different in terms of how they want their information 
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presented (208). “Active seekers” want to know everything right away about their condition 
and all its treatment options. “Selective seekers” just want a trickle of information, just 
enough to make the decisions they need to make today. “Information avoiders” want to have 
information and decisions filtered through someone else, often a family member or friend 
(208). Finally, and worst of all, paternalism has been abused, both at the bedside and in 
clinical research, resulting in modern malpractice and informed consent laws (209).
B. Autonomy
A newer model, fueled by the Internet, is autonomy. Here the patient’s goals and methods 
for achieving them are assumed to be central, correct and absolute. The doctor becomes a 
“vending machine,” helping the patient procure whatever it is they want. In this model, a 
question about an alternative therapy might be answered by the doctor as follows: “I 
understand what you want to do. How can I help?” Advantages of this model include respect 
for patient values and goals, and allowance for different information gathering preferences. 
Disadvantages include underutilization of physician education and experience, and the fact 
that the information being used by the patient to make their decision may be flawed or 
inaccurate (210).
C. Shared Decision Making
In between paternalism and autonomy is “shared decision making.” Here the patient’s values 
and goals are central, but recognized to be fluid and potentially modifiable based on new 
information. The physician helps define the pros and cons of different treatment options 
being considered, and may even make a suggestion based on their own synthesis of the data 
and their clinical experience. This model utilizes the talents and the skill set of the physician 
while sill allowing the patient to ultimately define their values, goals, acceptable risks and 
benefits. There is data suggesting that shared decision making is preferred by both patients 
(211) and doctors (212) and associated with improved compliance and better health 
outcomes (213). This biggest problem with shared decision making is that it takes 
significantly more physician time than paternalism or autonomy.
A group called ALSUntangled has developed a “shared shared decision making” model that 
helps with this time issue (210). There are 3 parts to this: inputs, reviews and outputs. Inputs 
on alternative ALS therapies come from patients and families, either via face to face visits 
with clinicians that are part of the group, or via email or Twitter (@alsuntangled). Reviews 
follow a specific standard operating procedure, with a group of 100 investigators from 
across 10 countries grading each alternative therapy’s mechanism, preclinical data, case 
reports, trials and risk (214). Outputs follow a standard format as well, and are published via 
free open access in the journal Amyotrophic Lateral Sclerosis and Frontotemporal 
Degeneration and on the website www.alsuntangled.org. Now when a patient asks about an 
alternative therapy, a busy clinician that wants to engage in shared decision making can refer 
them to an ALSUntangled review, rather than have to repeat the research themselves.
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Patients with ALS often consider CAM options, especially diets, nutritional supplements, 
cannabis, acupuncture, chelation and energy healing. This chapter reviews these CAM 
options for patients and clinicians who opt to engage in shared decision making. 
ALSUntangled is an international program that utilizes shared shared decision making to 
objectively review CAM options, reducing some of the physician time burden while helping 
patients make more informed treatment decisions.
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1. Patients with ALS often consider complementary and alternative therapies they 
read about on the Internet.
2. Common types of alternative therapies considered for ALS include special diets, 
nutritional supplements, cannabis, acupuncture, chelation and energy healing.
3. Physicians may handle discussions about alternative therapies via paternalism, 
autonomy or shared decision-making.
4. ALSUntangled reviews alternative therapies via a shared shared decision 
making model.
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